Ad
related to: ons guidelines for chemo administration
Search results
Results From The WOW.Com Content Network
ONS is also accredited as a provider of continuing education by the California Board of Registered Nursing, Provider #2850. [3] [4] ONS offers online and in-person education for oncology nurses to stay current on the latest cancer treatments and symptom management techniques. The society also holds both in-person and e-conferences.
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via ...
The Oncology Nursing Certification Corporation (ONCC) offers several different options for board certification in oncological nursing. [2] Certification is a voluntary process and ensures that a nurse has proper qualifications and knowledge of a specialty area and has kept up-to-date in his or her education.
Chemotherapy is one of the major categories of the medical discipline specifically devoted to pharmacotherapy for cancer, which is called medical oncology. [1] [2] The term chemotherapy now means the non-specific use of intracellular poisons to inhibit mitosis (cell division) or to induce DNA damage (so that DNA repair can augment chemotherapy ...
High-dose chemotherapy (HDC) is a regimen of chemotherapy medicines given at larger dosages. This therapeutic strategy is used to treat some cancers, especially those that are aggressive or have a high chance of coming back. With increased doses of chemotherapy chemicals administered to the body, HDC seeks to optimize the death of cancer cells.
As of 2007, ABVD is widely used as the initial chemotherapy treatment for newly diagnosed Hodgkin lymphoma. [citation needed] It has been the most effective and least toxic chemotherapy regimen available for treating early-stage Hodgkin Lymphoma. [1]
"7+3" in the context of chemotherapy is an acronym for a chemotherapy regimen that is most often used today (as of 2014) as first-line induction therapy (to induce remission) in acute myelogenous leukemia, [1] [2] excluding the acute promyelocytic leukemia form, which is better treated with ATRA and/or arsenic trioxide and requires less chemotherapy (if requires it at all, which is not always ...
Chemotherapy-induced nausea and vomiting may require antiemetics (such as ondansetron), and hemorrhagic cystitis is prevented with administration of mesna. Alopecia (hair loss) is common. [5] Neutropenia generally develops in the second week. During this period, many clinicians recommend pegfilgrastim or prophylactic use of ciprofloxacin.